

In claim 59, please replace the phrase "matrix anchor" with the phrase --head or tail--.

Attached hereto is the Appendix showing the changes made to the claims.

#### REMARKS

Claims 57 and 59 have been amended to define the invention with more clarity and particularity. Support for the amendments to claims 57 and 59 can be found throughout the specification and in particular at page 22. No new matter has been added as a result of these amendments. Claims 57-60 remain before the Examiner. Applicants respectfully request reconsideration and reexamination of the claims in their presently amended state.

In the previous Office Action, the Examiner has rejected claims 57-60 under the first paragraph of 35 U.S.C. § 112 for a lack of written description and enablement. Applicants respectfully argue against this rejection for the reasons of record. In particular, Applicants point out the previously submitted publication by Mikawa, et al., showing the use of the application-disclosed methods and compositions for expressing desired polypeptides fused to a phage head protein pD. Together with the detailed description of the instant specification, Applicants respectfully submit that the specification does provide adequate description and enabling disclosure of the claimed invention.

#### SUMMARY

In view of the amendments to the claims and for the reasons set forth above, Applicants respectfully submit that the claims are

08/852,020

TSRI 432.0 D1

now in a condition of allowance. An early notification to that effect is hereby earnestly solicited.

Respectfully submitted,

11-22-02

DATE

By: Thomas E. Northrup  
Thomas E. Northrup, Reg. No. 33,268

THE SCRIPPS RESEARCH INSTITUTE  
Office of Patent Counsel  
10550 North Torrey Pines Road  
Mail Drop TPC 8  
La Jolla, California 92037  
(858) 784-2937

☒ [X] Attorney or agent of  
record  
☐ [ ] Filed under §1.34a

P:\NANCY\WP\OA\2002\SCR1912P.PRELIM.AMEND

APPENDIX

VERSION OF CLAIMS WITH MARKINGS TO SHOW CHANGES MADE

A marked-up version of amended claims 57 and 59 is provided as follows:

57. (twice amended) A recombinant lambdoid bacteriophage vector comprising a nucleotide sequence that (i) defines the lambdoid elements for replication and packaging of the vector into an assembled bacteriophage, and (ii) encodes a conditionally suppressible cistron for expression of a matrix anchor protein and a fusion protein that comprises:

- a) a promoter for transcribing the cistron,
- b) a first upstream translatable sequence that encodes a lambdoid bacteriophage [matrix anchor] head or tail protein,
- c) a first ribosome binding site to initiate translation of said upstream translatable sequence,
- d) a second translatable sequence operatively linked downstream to said first translatable sequence that (i) encodes a linker polypeptide in frame with said [matrix anchor] head or tail protein and (ii) includes a sequence adapted for ligation of an insert polynucleotide that defines a third translatable sequence downstream from said second translatable sequence that encodes a preselected polypeptide, and
- e) a suppressor termination codon within said second translatable sequence that upon suppression results in read-through to form a fusion polypeptide consisting of said matrix anchor protein, linker polypeptide and preselected polypeptide.

59. (once amended) A recombinant lambdoid bacteriophage comprising a matrix of proteins encapsulating a lambdoid genome encoding a fusion protein, said matrix including said fusion protein, surface accessible in said matrix, and said fusion protein consists of, in the direction of amino terminus to carboxy terminus, a lambdoid bacteriophage [matrix anchor] head or tail protein, a linker polypeptide and a preselected polypeptide.